Novel vaccine approach to address osteoarthritis pain

May 8, 2019 0 By FM

Isabell S von Loga et al developed a new vaccine which demonstrates therapeutic efficiency of anti-nerve growth factor (NGF) antibodies in helping alleviate pain in osteoarthritis (OA) patients. NGF is a validated drug target for pain in osteoarthritis. The vaccine was developed from virus-like particles that were derived from cucumber mosaic virus (CuMV) and coupled to expressed recombinant NGF. The mice used in the study had underwent partial meniscectomy causing uneven distribution of weight across their lower limbs to induce osteoarthritis pain. Spontaneous pain behaviour was measured, and osteoarthritis severity was quantified. The cohort was inoculated either before surgery or once when pain was established. Rise in anti-NGF titre was readily observed in the vaccinated mice. Regular boosting with fresh vaccine was required to maintain the antibody level in the sentinel mice cohort. Researchers observed a reversal of pain behaviour through incapacitance testing. The study brings forth a novel vaccine strategy for the first time in helping reduce osteoarthritis pain. It potentially offers an easier alternative to pain which might help stop reliance of OA patients over painkillers.

Source: Annals of the Rheumatic Diseases March 12,2019 https://ard.bmj.com/content/early/2019/03/08/annrheumdis-2018-214489.info